The COVID-19 medication developed by GlaxoSmithKline appears to be effective against the novel omicron form, according to the company. The omicron version has been confirmed in India for the first time. For the most up-to-date information, keep an eye on DW.
In a pre-clinical study, GlaxoSmithKline’s antibody-based COVID-19 therapy, developed in collaboration with VIR Biotechnology in the United States, also worked against the virus’s novel omicron form.
The tests were carried out on hamsters infected with bio-engineered coronavirus variants that have mutations comparable to those found in the omicron form. The sotrovimab therapy will be subjected to more testing.
The medicine was licensed in the United Kingdom on Thursday to treat those who are at high risk of developing severe COVID symptoms.
On Thursday, the Medicines and Healthcare Products Regulatory Agency (MHRA) announced that the monoclonal antibody “was found to be safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease.”
